Fig. 2.
Investigator-assessed PFS and OS. a, investigator-assessed PFS. b, OS. D IV intravenous docetaxel, H SC subcutaneous trastuzumab, NR not reported, OS overall survival, P IV intravenous pertuzumab, PFS progression-free survival
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.